Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.30 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.30 |
| ▸ | PGR | P06401 | 1/20 | 0.30 |
| ▸ | FLT3 | P36888 | 1/20 | 0.30 |
| ▸ | AHR | P35869 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17187905 | 0.87 | CYP1A2 (0.37) | CYP1A2CYP2A6IDO1NR3C1NR3C2 | |
| SCHEMBL22967807 | 0.81 | CYP1A2 (0.43) | CYP1A2CYP2A6IDO1HTR6MEN1 | |
| SCHEMBL5644819 | 0.79 | ALDH1A1 (0.40) | CYP1A2CYP2A6NR3C1 | |
| SCHEMBL18428154 | 0.75 | HTR6 (0.39) | CYP1A2CYP2A6IDO1HTR6PARP1 | |
| SCHEMBL3866351 | 0.73 | CA2 (0.34) | — | |
| SCHEMBL18428147 | 0.72 | — | — | |
| SCHEMBL29700966 | 0.72 | KCNN4 (0.37) | MEN1KMT2A | |
| SCHEMBL19924965 | 0.72 | KCNN4 (0.37) | MEN1KMT2A | |
| SCHEMBL17187828 | 0.71 | CYP2A6 (0.37) | CYP1A2CYP2A6HTR6AHR | |
| SCHEMBL1243594 | 0.71 | GPR84 (0.47) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3134392-B1 | SULFONAMIDE DERIVATIVES AND PHARMACEUTICAL APPLICATIONS THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2019-01-02 | — | — | EP | disclosed |
| US-9840482-B2 | Sulfonamide derivatives and pharmaceutical applications thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-12-12 | — | — | US | disclosed |
| EP-3134392-A1 | SULFONAMIDE DERIVATIVES AND PHARMACEUTICAL APPLICATIONS THEREOF | Sunshine Lake Pharma Co., Ltd. (CN) | 2017-03-01 | — | — | EP | disclosed |
| US-20170037017-A1 | Sulfonamide Derivatives And Pharmaceutical Applications Thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-02-09 | — | — | US | disclosed |
| WO-2015158313-A1 | SULFONAMIDE DERIVATIVES AND PHARMACEUTICAL APPLICATIONS THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037017-A1 | Sulfonamide Derivatives And Pharmaceutical Applications Thereof | HTR6, SLC6A4, HTR2A | CYP1A2 376/4885CYP2A6 26/4885IDO1 717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.